# Lineage Cell Therapeutics, Inc.: overview LCTX · NYSE · CIK 876343 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/lctx.md) · [Financials](/companies/lctx/financials.md) · [Filings](/companies/lctx/filings.md) · [Insiders](/companies/lctx/insiders.md) Latest reported revenue: [$1.1m](/filings/0001193125-26-338064.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 6, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001193125-26-338064). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $k | [3,779](/filings/0001193125-25-269599.md) | [2,868 d](/filings/0001193125-26-093992.md) | [1,502](/filings/0001193125-26-219479.md) | [2,765](/filings/0001193125-26-338064.md) | [3,681](/filings/0001193125-25-269599.md) | [6,608 d](/filings/0001193125-26-093992.md) | [1,725](/filings/0001193125-26-219479.md) | [1,069](/filings/0001193125-26-338064.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(101.6%)](/filings/0001193125-25-269599.md) | [(178.2%) d](/filings/0001193125-26-093992.md) | [(433.1%)](/filings/0001193125-26-219479.md) | [(715.4%)](/filings/0001193125-26-338064.md) | [(102.9%)](/filings/0001193125-25-269599.md) | [(99.1%) d](/filings/0001193125-26-093992.md) | [(440.2%)](/filings/0001193125-26-219479.md) | [(834.7%)](/filings/0001193125-26-338064.md) | | Net margin | % | [(80.3%)](/filings/0001193125-25-269599.md) | [(114.1%) d](/filings/0001193125-26-093992.md) | [(275.6%)](/filings/0001193125-26-219479.md) | [(1101.8%)](/filings/0001193125-26-338064.md) | [(809.0%)](/filings/0001193125-25-269599.md) | [12.9% d](/filings/0001193125-26-093992.md) | [(279.0%)](/filings/0001193125-26-219479.md) | [138.6%](/filings/0001193125-26-338064.md) | | Diluted EPS | $ per share | [(0.02)](/filings/0001193125-25-269599.md) | not reported | [(0.02)](/filings/0001193125-26-219479.md) | [(0.13)](/filings/0001193125-26-338064.md) | [(0.13)](/filings/0001193125-25-269599.md) | not reported | [(0.03)](/filings/0001193125-26-219479.md) | [(0.03)](/filings/0001193125-26-338064.md) | | Free cash flow | $k | [(5,899) d](/filings/0001193125-25-269599.md) | [(6,711) d](/filings/0001193125-26-093992.md) | [(4,983)](/filings/0001193125-26-219479.md) | [(5,553) d](/filings/0001193125-26-338064.md) | [(3,628) d](/filings/0001193125-25-269599.md) | [(5,277) d](/filings/0001193125-26-093992.md) | [(8,133)](/filings/0001193125-26-219479.md) | [(7,352) d](/filings/0001193125-26-338064.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [4.3](/filings/0001493152-23-007129.md) | [14.7](/filings/0000950170-24-027988.md) | [8.9](/filings/0000950170-25-036309.md) | [9.5](/filings/0001193125-26-093992.md) | [14.6](/filings/0001193125-26-093992.md) | | Gross margin | % | [67.2%](/filings/0001493152-23-007129.md) | [95.0%](/filings/0000950170-24-027988.md) | [92.5%](/filings/0000950170-24-027988.md) | not reported | not reported | | Operating margin | % | [(1133.6%)](/filings/0001493152-23-007129.md) | [(153.2%)](/filings/0000950170-24-027988.md) | [(276.5%)](/filings/0000950170-25-036309.md) | [(226.1%)](/filings/0001193125-26-093992.md) | [(251.6%)](/filings/0001193125-26-093992.md) | | Net margin | % | [(991.0%)](/filings/0001493152-23-007129.md) | [(178.7%)](/filings/0000950170-24-027988.md) | [(240.2%)](/filings/0000950170-25-036309.md) | [(195.9%)](/filings/0001193125-26-093992.md) | [(436.5%)](/filings/0001193125-26-093992.md) | | Diluted EPS | $ per share | [(0.26)](/filings/0001493152-22-006520.md) | [(0.15)](/filings/0000950170-24-027988.md) | [(0.12)](/filings/0000950170-25-036309.md) | [(0.09)](/filings/0001193125-26-093992.md) | [(0.28)](/filings/0001193125-26-093992.md) | | Free cash flow | $m | [(23.9)](/filings/0001493152-23-007129.md) | [0.6](/filings/0000950170-24-027988.md) | [(29.2)](/filings/0000950170-25-036309.md) | [(23.7)](/filings/0001193125-26-093992.md) | [(19.4)](/filings/0001193125-26-093992.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareBasicAndDiluted; Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/lctx/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [BROADWOOD CAPITAL INC](/funds/1278387.md) | 2026-06-30 | $64.9m | 49,560,992 | | Unchanged | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $17.3m | 13,186,895 | | Added +9,322,138 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $11.9m | 9,054,918 | | Added +736,233 | | [Defender Capital, LLC.](/funds/1766929.md) | 2026-06-30 | $8.6m | 6,598,899 | | Reduced −130,700 | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $6.9m | 5,299,457 | | Added +2,776,343 | | [RAFFLES ASSOCIATES LP](/funds/1169581.md) | 2026-06-30 | $6.8m | 5,197,788 | | Reduced −165,000 | | [FIFTH THIRD BANCORP](/funds/35527.md) | 2026-06-30 | $6.0m | 4,600,000 | | Unchanged | | [MILLENNIUM MANAGEMENT LLC](/funds/1273087.md) | 2026-06-30 | $4.0m | 3,018,567 | | Reduced −2,542,807 | | [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $3.0m | 2,314,180 | | Added +1,224,069 | | [VANGUARD FIDUCIARY TRUST CO](/funds/933478.md) | 2026-06-30 | $2.2m | 1,668,629 | | Added +344,471 | ## Recent filings [All 1,330 filings](/companies/lctx/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-08-06 | 16:16 ET | [10-Q](/filings/0001193125-26-338064.md) | Quarterly report, period 2026-06-30 | 0001193125-26-338064 | | 2026-08-06 | 16:11 ET | [8-K](/filings/0001193125-26-338020.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-338020 | | 2026-06-12 | 16:32 ET | [8-K](/filings/0001193125-26-269557.md) | 5.07 Shareholder vote results; 8.01 Other events | 0001193125-26-269557 | | 2026-05-12 | 16:15 ET | [10-Q](/filings/0001193125-26-219479.md) | Quarterly report, period 2026-03-31 | 0001193125-26-219479 | | 2026-05-12 | 16:10 ET | [8-K](/filings/0001193125-26-219421.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-219421 | | 2026-04-29 | 16:10 ET | [DEF 14A](/filings/0001193125-26-191556.md) | Proxy statement, period 2026-04-29 | 0001193125-26-191556 | | 2026-03-11 | 09:00 ET | [8-K](/filings/0001193125-26-101167.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-101167 | | 2026-03-05 | 16:16 ET | [10-K](/filings/0001193125-26-093992.md) | Annual report, period 2025-12-31 | 0001193125-26-093992 | | 2026-03-05 | 16:10 ET | [8-K](/filings/0001193125-26-093948.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-093948 | | 2025-11-28 | 16:05 ET | [8-K](/filings/0001193125-25-302552.md) | 8.01 Other events | 0001193125-25-302552 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001193125-26-093992.md), filed Mar 5, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/c70d3618-e613-41a4-b391-24f1cb7d98b1) ## About the filer - CIK: 876343 - Tickers: LCTX - Exchange: NYSE - SIC code: 2836 Biological Products, (No Diagnostic Substances) - State of incorporation: CA - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:26 ET. No prices; not investment advice.